RAFAEL HOLDINGS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RAFAEL HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2020-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2020-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2020-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-10-31 was $15.67M.
- RAFAEL HOLDINGS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $15.67M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2020-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | $15.67M 10-K · filed 2021-10-18 |
| 2020-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | |
| 2020-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-17 | |
| 2019-10-31 | $15.67M 10-Q · filed 2020-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |